APA (7th ed.) Citation

R, S., M, K., D, K., L, H., TM, F., W, S., . . . CP, D. (2023). Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis. Arthritis & rheumatology (Hoboken, N.J.), 75(9), 1608. https://doi.org/10.1002/art.42510

Chicago Style (17th ed.) Citation

R, Spiera, et al. "Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis." Arthritis & Rheumatology (Hoboken, N.J.) 75, no. 9 (2023): 1608. https://doi.org/10.1002/art.42510.

MLA (9th ed.) Citation

R, Spiera, et al. "Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis." Arthritis & Rheumatology (Hoboken, N.J.), vol. 75, no. 9, 2023, p. 1608, https://doi.org/10.1002/art.42510.